Difference between revisions of "Interferon gamma-1a (Imunomax-γ)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. ==D...") |
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
||
| Line 4: | Line 4: | ||
*[[Cutaneous T-cell lymphoma]] | *[[Cutaneous T-cell lymphoma]] | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| − | *2014-05-23: | + | *2014-05-23: New additional indications and a new dosage for the treatment of [[Cutaneous T-cell lymphoma|mycosis fungoides and Sézary syndrome]]. |
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Imunomax-γ | *'''Brand name:''' Imunomax-γ | ||
Revision as of 01:51, 11 June 2023
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Diseases for which it is used
History of changes in PMDA indication
- 2014-05-23: New additional indications and a new dosage for the treatment of mycosis fungoides and Sézary syndrome.
Also known as
- Brand name: Imunomax-γ